News for Avidity Biosciences, Inc. (RNA)

Read the latest analysis on Avidity Biosciences' stock here.

U.S. stocks were lower, with the Dow Jones index falling around 0.1% on Monday. Shares of Veritex Holdings, Inc. VBTX rose sharply during Monday's session afte...

Evercore ISI analyst Gavin Clark-Gartner has increased the price target for Avidity Biosciences (RNA) from $60 to $70 while maintaining an Outperform rating on

Goldman Sachs has resumed its evaluation of Avidity Biosciences (RNA), giving it a Buy rating and setting a price target at $55. The financial institution antic

In recent developments for Avidity Biosciences (RNA), Cantor Fitzgerald has decided to maintain its positive outlook on the company. Analyst Eric Schmidt reiter

On June 17, 2025, Wolfe Research initiated coverage on Avidity Biosciences (RNA), providing investors with new insights into the biotechnology company. The este

Wolfe Research has initiated coverage on Avidity Biosciences (RNA) with an Outperform rating and set a price target of $55. The company, currently at a clinical

Wolfe Research has begun covering Avidity Biosciences (RNA), assigning the company an Outperform rating. The firm has set a price target of $55 for the stock. T

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started coverage of Avidity Biosciences, Inc.

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started coverage of Avidity Biosciences, Inc. (NASDAQ:RNA), with a Strong Buy rating and a price objective of $65. The rating is part of a larger biotech sector note, in which the firm sees favorable risk/reward across the […]

In a recent update from Citigroup, analyst Geoff Meacham has maintained Avidity Biosciences' (RNA)

In a recent update, JP Morgan analyst Gena Wang has maintained the "Overweight" rating for Avidity Biosciences (RNA). The announcement was accompanied by an inc

U.S. stock futures pointed to a mixed opening on Tuesday, June 10, 2025, as investors digest yesterday's market performance and await key economic data. The

Avidity Biosciences (RNA) has seen its stock price target raised by Citi analyst Geof Meacham, moving up from $70 to $75, while maintaining a Buy rating. This a

Barclays has increased its price target for Avidity Biosciences (RNA) from $57 to $59, maintaining an Overweight rating on the stock. This change follows a rece

Summary Avidity Biosciences Inc (RNA), a biopharmaceutical company focused on developing RNA therapeutics, announced on May 21, 2025, that it has granted non-qu

Avidity Biosciences (RNA) grants inducement equity awards to 16 new non-executive employees. The awards include 71,000 stock options with an exercise pr

**media[626854]**

On May 9, 2025, Avidity Biosciences (RNA) continued to receive positive feedback from analysts as Chardan Capital's Keay Nakae maintained a 'Buy' rating on the